Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children
- PMID: 20546586
- PMCID: PMC2905419
- DOI: 10.1186/1471-2334-10-168
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children
Abstract
Background: Influenza vaccination in infants and children with existing health complications is current practice in many countries, but healthy children are also susceptible to influenza, sometimes with complications. The under-recognised burden of disease in young children is greater than in elderly populations and the number of paediatric influenza cases reported does not reflect the actual frequency of influenza.
Discussion: Vaccination of healthy children is not widespread in Europe despite clear demonstration of the benefits of vaccination in reducing the large health and economic burden of influenza. Universal vaccination of infants and children also provides indirect protection in other high-risk groups in the community. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the vaccination of infants and children against influenza. The aim of CEVAG is to encourage the efficient and safe use of vaccines to prevent and control infectious diseases.
Summary: CEVAG recommends the introduction of universal influenza vaccination for all children from the age of 6 months. Special attention is needed for children up to 60 months of age as they are at greatest risk. Individual countries should decide on how best to implement this recommendation based on their circumstances.
Similar articles
-
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination.Vaccine. 2010 May 14;28(22):3758-66. doi: 10.1016/j.vaccine.2010.03.072. Epub 2010 Apr 7. Vaccine. 2010. PMID: 20380902
-
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines.Eur J Pediatr. 2009 Sep;168(9):1031-5. doi: 10.1007/s00431-009-0972-6. Epub 2009 Mar 20. Eur J Pediatr. 2009. PMID: 19301033
-
Childhood and adolescent influenza vaccination in Europe: A review of current policies and recommendations for the future.Expert Rev Vaccines. 2016 May;15(5):659-70. doi: 10.1586/14760584.2016.1138861. Epub 2016 Feb 16. Expert Rev Vaccines. 2016. PMID: 26879817 Review.
-
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Oct 10;41(10):1555-1576. doi: 10.3760/cma.j.cn112338-20200904-01126. Zhonghua Liu Xing Bing Xue Za Zhi. 2020. PMID: 33297613 Chinese.
-
Protection of young children from influenza through universal vaccination.Hum Vaccin Immunother. 2015;11(10):2350-8. doi: 10.1080/21645515.2015.1055428. Hum Vaccin Immunother. 2015. PMID: 26090704 Free PMC article. Review.
Cited by
-
Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.Hum Vaccin Immunother. 2013 Mar;9(3):707-11. doi: 10.4161/hv.23269. Epub 2013 Jan 7. Hum Vaccin Immunother. 2013. PMID: 23295894 Free PMC article.
-
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.BMC Infect Dis. 2014 Jan 22;14:40. doi: 10.1186/1471-2334-14-40. BMC Infect Dis. 2014. PMID: 24450996 Free PMC article.
-
Overview of the pediatric healthcare system in Romania.Turk Pediatri Ars. 2020 Sep 1;55(Suppl 1):69-84. doi: 10.14744/TurkPediatriArs.2020.77775. eCollection 2020. Turk Pediatri Ars. 2020. PMID: 32963483 Free PMC article. Review.
-
Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children.Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1107-13. doi: 10.1007/s10096-016-2641-9. Epub 2016 Apr 16. Eur J Clin Microbiol Infect Dis. 2016. PMID: 27086364
-
The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies.Influenza Other Respir Viruses. 2018 Jul;12(4):438-445. doi: 10.1111/irv.12555. Epub 2018 Apr 10. Influenza Other Respir Viruses. 2018. PMID: 29573143 Free PMC article. Clinical Trial.
References
-
- World Health Organization. Fact sheet No 211. http://www.who.int/mediacentre/factsheets/fs211/en/index.html
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical